Abstract: The present invention is directed to methods of administering foretinib or pharmaceutically acceptable salts or solvates thereof a c-Met inhibitor to a patient in need thereof comprising: determining whether said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene; and if said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a pharmaceutical composition comprising foretinib or a pharmaceutically acceptable salt thereof.